Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Abstract Sodium-glucose co-transporter-2 inhibitors are used in the treatment of diabetes but are also emerging as cardioprotective agents in heart diseases even in the absence of type 2 diabetes. In this paper, upon providing a short overview of common pathophysiological features of diabetes, we re...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-04-01
|
| Series: | Cardiovascular Diabetology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12933-023-01822-7 |
| _version_ | 1797836589739540480 |
|---|---|
| author | Julia Hoehlschen Dominik Hofreither Tamara Tomin Ruth Birner-Gruenberger |
| author_facet | Julia Hoehlschen Dominik Hofreither Tamara Tomin Ruth Birner-Gruenberger |
| author_sort | Julia Hoehlschen |
| collection | DOAJ |
| description | Abstract Sodium-glucose co-transporter-2 inhibitors are used in the treatment of diabetes but are also emerging as cardioprotective agents in heart diseases even in the absence of type 2 diabetes. In this paper, upon providing a short overview of common pathophysiological features of diabetes, we review the clinically reported cardio- and nephroprotective potential of sodium-glucose co-transporter-2 inhibitors currently available on the market, including Dapagliflozin, Canagliflozin, and Empagliflozin. To that end, we summarize findings of clinical trials that have initially drawn attention to the drugs’ organ-protective potential, before providing an overview of their proposed mechanism of action. Since we particularly expect that their antioxidative properties will broaden the application of gliflozins from therapeutic to preventive care, special emphasis was put on this aspect. |
| first_indexed | 2024-04-09T15:12:27Z |
| format | Article |
| id | doaj.art-019e5a1a87bf4c57bc41b668b7d0cdf0 |
| institution | Directory Open Access Journal |
| issn | 1475-2840 |
| language | English |
| last_indexed | 2024-04-09T15:12:27Z |
| publishDate | 2023-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj.art-019e5a1a87bf4c57bc41b668b7d0cdf02023-04-30T11:06:36ZengBMCCardiovascular Diabetology1475-28402023-04-0122111010.1186/s12933-023-01822-7Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative reviewJulia Hoehlschen0Dominik Hofreither1Tamara Tomin2Ruth Birner-Gruenberger3Institute of Chemical Technologies and Analytics, TU WienInstitute of Chemical Technologies and Analytics, TU WienInstitute of Chemical Technologies and Analytics, TU WienInstitute of Chemical Technologies and Analytics, TU WienAbstract Sodium-glucose co-transporter-2 inhibitors are used in the treatment of diabetes but are also emerging as cardioprotective agents in heart diseases even in the absence of type 2 diabetes. In this paper, upon providing a short overview of common pathophysiological features of diabetes, we review the clinically reported cardio- and nephroprotective potential of sodium-glucose co-transporter-2 inhibitors currently available on the market, including Dapagliflozin, Canagliflozin, and Empagliflozin. To that end, we summarize findings of clinical trials that have initially drawn attention to the drugs’ organ-protective potential, before providing an overview of their proposed mechanism of action. Since we particularly expect that their antioxidative properties will broaden the application of gliflozins from therapeutic to preventive care, special emphasis was put on this aspect.https://doi.org/10.1186/s12933-023-01822-7SGLT-2EmpagliflozinCanagliflozinDapagliflozinHeart failureOxidative stress |
| spellingShingle | Julia Hoehlschen Dominik Hofreither Tamara Tomin Ruth Birner-Gruenberger Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review Cardiovascular Diabetology SGLT-2 Empagliflozin Canagliflozin Dapagliflozin Heart failure Oxidative stress |
| title | Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review |
| title_full | Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review |
| title_fullStr | Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review |
| title_full_unstemmed | Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review |
| title_short | Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review |
| title_sort | redox driven cardioprotective effects of sodium glucose co transporter 2 inhibitors comparative review |
| topic | SGLT-2 Empagliflozin Canagliflozin Dapagliflozin Heart failure Oxidative stress |
| url | https://doi.org/10.1186/s12933-023-01822-7 |
| work_keys_str_mv | AT juliahoehlschen redoxdrivencardioprotectiveeffectsofsodiumglucosecotransporter2inhibitorscomparativereview AT dominikhofreither redoxdrivencardioprotectiveeffectsofsodiumglucosecotransporter2inhibitorscomparativereview AT tamaratomin redoxdrivencardioprotectiveeffectsofsodiumglucosecotransporter2inhibitorscomparativereview AT ruthbirnergruenberger redoxdrivencardioprotectiveeffectsofsodiumglucosecotransporter2inhibitorscomparativereview |